Global Study of Del-desiran for the Treatment of DM1

Key facts

Sponsor

Avidity Biosciences, Inc.

Intervention

AOC 1001 (del-desiran)(drug)

Enrollment

159 enrolled

Eligibility

16-65 years · All sexes

Timeline

2024 – 2026

Study locations (30)

• Stanford University, Stanford, California, United States
• University of Colorado, Denver, Colorado, United States
• University of Florida, Gainesville, Florida, United States
• University Research Center of South Florida, Tampa, Florida, United States
• Indiana University (IU), Indianapolis, Indiana, United States
• Kansas University Medical Center, Kansas City, Kansas, United States
• Kennedy Krieger Institute, Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• University of Rochester Medical Center, Rochester, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• Wake Forest, Winston-Salem, North Carolina, United States
• University of Cincinnati Gardner Neuroscience Institute, Cincinnati, Ohio, United States
• Ohio State University, Columbus, Ohio, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thomsen and Becker disease

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT07008469
  Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.

See all trials for Thomsen and Becker disease →